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doi:10.1016/j.ejvs.2009.01.003Abstract Early results of a thrupass endograft in the treatment of femoral lesions are prom-
ising. Less morbidity and better cost-effectiveness are suggested to be achieved in the treat-
ment of chronic lower limb ischaemia with endovascular treatment compared to surgical
treatment.
Patients and methods: This randomised multicentre trial aimed to enroll a group of 60þ 60
patients for the treatment of 5e25-cm occlusions of superficial femoral artery (SFA) to be fol-
lowed up for 3 years. Patients were treated either with endoluminal PTFE thrupass (WL Gore &
Ass) or with surgical polytetrafluoroethylene (PTFE) bypass to proximal popliteal artery.
Primary patency at 3 years was scheduled to be the primary end-point and secondary patency,
functional success, costs and quality of life the secondary end-points.
Results: A sample of 100 consecutive SFA occlusions in one of the centres revealed that only 4%
of the lesions were amenable for the study. The trial was prematurely terminated due to the
results of an interim analysis at the time when 44 patients were recruited: the 1-year primary
patency (excluding technical failures) was 48% for thrupass and 95% for bypass (pZ 0.02). The
patency difference in favour of surgical bypass over endovascular thrupass was also sustained
after completion of 1-year follow-up, the primary patencies being 46% and 84% at 1 year with
grossly equilinear life-table curves thereafter (pZ 0.18), respectively. The corresponding
secondary patencies were 63% and 100% (pZ 0.05) when excluding technical failures and
58% and 100% (pZ 0.02) according to intention-to-treat analysis. Secondary outcomes were
thus not analysed.
Conclusion: Treatment of SFA occlusions (TASC IIB and C or Imelda Ia and II) should be done by
PTFE bypass rather than by PTFE thrupass, as thrupass is connected with worse early outcome.
These results represent only a small category of femoral disease.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.o, Department of Vascular Surgery, Helsinki University Central Hospital, P.O. Box 340, FIN-00029 HUS,
282; fax: þ358 9 4717 3548.
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Bypass or Thrupass for SFA Occlusion? 579Although the primary treatment of claudication due to the disease, that is, critical ischaemia or claudication with
femoropopliteal obstruction is conservative, bypass surgery
may help patients who are resistant to exercise and
compensatory ability of collateral circulation. Acceptable
results of PTFE-graft bypass to a proximal popliteal artery
may justify its use in the treatment of chronic lower limb
ischaemia. As data suggest that patency achieved is similar
to venous conduits, some authors have recommended PTFE
graft to beused as thefirst choice for femoropopliteal above-
knee bypass.1,2 The rationale for this recommendation is to
save the vein for further bypass surgery as the patency of
femorocrural bypasswith PTFE is far lower than that of a vein
bypass. This approach is not unanimously accepted.
Femoropopliteal occlusions can be treated endovascu-
larly by re-canalisation, balloon angioplasty and stenting or
by endoluminal thrupass.3,4 Patency rates are strongly
affected by the lesion treated and the run-off status, short
stenoses giving better results than long occlusions and
a good run-off giving better patency than a poor run-off.
Irrespective of the method used, endothelial injury,
development of pseudointimal hyperplasia and subsequent
restenosis and occlusion are a problem. The introduction of
an intraluminal stented endograft suggests an approach to
decrease the development of restenosis and occlusion,
leaving only the anastomotic sites vulnerable.
Endoluminal thrupass can be introduced percutaneously
in an angioradiological suite. Femoropopliteal bypass
necessitates exposure of the femoral bifurcation and the
popliteal artery medial to the popliteal fossa above the
knee and tunnelling of the graft. Operative morbidity
considerably exceeds that of the endovascular treatment.
Preliminary data revealed 1-year patency rates of 79e
93%5e7 after PTFE thrupass and 61e81% patency rates1,2,8
after surgical PTFE bypass.
It was optimistically hypothesised that better outcome
with less morbidity can be achieved with the thrupass
method. As there may be typical introductory-phase
publication bias in favour of the thrupass, it was hypoth-
esised that thrupass results in less morbidity, and it offers
a minimally invasive technique combined with a rapid
recovery time. Therefore, it is justified to compare these
therapeutic alternatives for treating patients with chronic
lower limb ischaemia.
This study aimed to compare PTFE-graft bypass surgery
to proximal popliteal versus PTFE-endograft for supervicial
femoral artery occlusion in intermittent claudication and
critical ischaemia in patients who would be technically
amenable for both treatments. The objective was, first, to
compare primary patencies of the two treatments, and
second, to evaluate secondary patency, functional status,




The current study was a prospective, randomised,
controlled, multicentre, clinical study. The study aimed to
enroll 15 vascular centres in Scandinavia. The patients were
to be stratified according to the centre and the severity ofno response to medical therapy and exercise. A 2-year
recruitment period and a 3-year post-intervention follow-
up period were planned.
The aim was to enroll a group of 2 60 patients to be
followed up for 3 years. An interim analysis was planned to
be made 1 year post-procedure.
Inclusion criteria
The target lesion was to be a superficial femoral artery
(SFA) occlusion ranging from 5 to 25 cm in length. Each
centre could determine the length within this range, but
the criteria were to be the same for both patient groups in
each centre. Adjacent inflow and outflow segments were to
be close to normal with the vessel diameter between 4.8
and 6.5 mm. At least one patent distal run-off vessel and at
least 1 cm of healthy SFA below and above the lesion were
required to allow proper placement of the endograft.
Exclusion criteria
Known allergy or contraindications to contrast medium or
adjuvant antithrombotic medication or bleeding diatheses,
presence of one or several previously placed endografts or
stents in the SFA segment (previous mere percutaneous
transluminal angioplasty (PTA) was not an exclusion crite-
rion) or other planned endovascular therapy of the same
segment were the specific exclusion criteria.
The presence of an evolving malignancy and any other
illness posing an immediate threat to life or life-expectancy
less than 2 years were the exclusion criteria in general.
Non-compliant patients and those participating in another
vascular clinical study less than 30 days prior to inclusion
were also excluded.
Clinical evaluation
Clinical evaluation of all patients included medical history
and vascular laboratory assessment including anklee
brachial index (ABI) measurement, limb status and quality-
of-life questionnaires. The suitability of any patient for this
trial was evaluated by duplex ultrasonography, magnetic
resonance angiography (MRA) or other radiological modali-
ties before angiography according to local hospital practice.
Patient characteristics
There were no major baseline differences between patient
groups (Tables 1 and 2). The mean length of occlusion was
11.4 cm; of the lesions, 30 were TASC IIB and 14 TASC IIC.
Moreover, there were seven occlusions ranging 20e25 cm in
length (Table 2).
Procedure
Investigators for this study were vascular surgeons and
interventional radiologists experienced in the diagnosis and
treatment of femoropopliteal occlusions.
The surgical procedure was a femoropopliteal bypass,
preferably with a 6-mm, non-coated, expanded PTFE
Table 1 Basic patient characteristics.
Variable Thrupass (nZ 23) Bypass (nZ 21)
Gender: male/
female
13 (57%)/10 (43%) 12 (57%)/9 (43%)




Diabetes 8 (35%) 3 (14%)
Dyslipidemia 16 (73%) 9 (43%)
Cerebro-vascular
disease
2 (9%) 2 (10%)
Hypertension 15 (68%) 12 (57%)
Cardiac disease 4 (18%) 6 (29%)
Pulmonary 3 (14%) 6 (29%)
Smoking 16 (70%) 15 (71%)
Renal 1 (5%) 2 (10%)
580 M. Lepa¨ntalo et al.(ePTFE) graft with inflow from the common femoral to
popliteal artery above the knee. After endovascular
re-canalisation and pre-dilatation, a Viabahn endograft
was implanted to reline the vessel lumen by the radiologist
in an angioradiological suite. The aim was to use preferably


















Length of occlusion e
mean (range)
10.3 (5e25) 12.6 (5e25)
TASC IIBa 87% (20/23) 76% (16/21)
TASC IICa 13% (3/23) 24% (5/21)
Imelda Iaa 91% (21/23) 90% (19/21)
Imelda IIa 9% (2/23) 10% (2/21)
Number of patent
crural vessels
1Z 7 (30%) 1Z 3 (14%)
2Z 7 (30%) 2Z 6 (29%)
3Z 9 (40%) 3Z 12 (57%)
Grafts used
Number of grafts Mean 1.43
(1Z 15, 2Z 4,
3Z 1, 4Z 1)
1




Diameter of grafts 5Z 1
6Z 12 6Z 20
7Z 6
8Z 2 8Z 1
a TASC IIBZ SFA occlusion >5e15 cm, TASC IICZ>15 cm,
Imelda IaZ 5e20 cm, Imelda IIZ>20 cm.by 5e20%. Intra-operative unfractionated heparin was
always administered. A prophylactic antibiotic was admin-
istered during the intervention according to the hospital
routine. Completion angiogram was mandatory to reveal
possible technical errors and for verification of the
morphological result in both groups.
The intention was to start acetylsalicylic acid immedi-
ately post-procedurally in both groups and continue at least
1 year, preferably lifelong. Some centres wished to use
clopidogrel aside or alone and, if so, the drug was to be
administered in both groups in a similar fashion. Low-
molecular-weight heparin was to be administered in both
groups for 2 days post-operatively.
Data collection
Clinical data were scheduled to be collected at the respec-
tive times of patient enrollment, procedure, discharge and
planned follow-ups at 2, 6, 12, 24 and 36months as well as at
patient death.
End-points
The primary end-point of the study was primary patency at
3 years after intervention. Patency had to be demonstrated
by duplex ultrasound or other imaging modalities at every
control visit. The ABI measurements were recorded to
assess the haemodynamic effect of the procedure.
Functional success, complications and costs were the
secondary end-points of the study. Functional success was
defined as a sustained ABI increase of 0.15 or more.
Suboptimal outcome was defined as the presence of any of
the following: restenosis diagnosed by colour duplex
ultrasonography, ABI improvement of less than 0.15 or
deterioration by more than 0.15 from the maximum post-
procedural value or re-intervention at the treated site.
Secondary patency was defined by procedures required to
re-establish or maintain blood flow after occlusion or
stenosis. As a subgroup of secondary patency, primary
assisted patency was defined, as procedures required
maintaining blood flow across the treated lesion before
occlusion.
Complications included post-procedural haemorrhage,
haematomas, cardiac, pulmonary and renal complications
and infection. Technical problems or equipment failure in
the endoprosthesis group were also recorded.
All additional vascular procedures of the study leg during
follow-up were reported. Wound revisions, skin transplants
or minor amputations were not considered to be additional
vascular procedures.
A procedural death was any death that occurred within
30 days of the procedure. Immediate functional failure was
one in which the threshold increase of ABI was not achieved
within 24 h. Early failure was any failure occurring within 30
days of the operation. Limb salvage was defined as reten-
tion of the leg without any major amputation or death.
Statistics
The primary aim of the statistical analysis was to show that
the clinical performance of the new procedure was not
Table 3 Immediate outcome.
Variable Thrupass Bypass























1 Redo 1 Outflow PTA
Length of hospital
stay e mean (range)
1.7 (0e7) 4.5 (2e10)
Procedure related complications (<30 days)
Graft occlusions 2 0
Haematoma 3 0
Peripheral embolism 2 0
Vessel perforation 1 0
Other complications 1 (Pain, fever and
increased CRP)
1 (Oedema)
Infection (superficial) 0 3
Infection (graft) 0 1




Bypass or Thrupass for SFA Occlusion? 581inferior to the previously accepted surgical treatment for
chronic lower limb ischaemia. Analysis was done according
to the intention-to-treat principle. Thus the patient stayed
included in the assigned group irrespective of any further
procedures needed.
Patencies were presented as life-table data estimates.
The log-rank (ManteleCox) test was used to test equality of
patency distributions for the different levels.
Ethical aspects
All eligible patients were to be invited to participate in the
study. There was a patient information letter given to each
eligible patient. Based on the written and spoken infor-
mation, the patient made the decision whether or not to
join the study. The investigator obtained a signed patient
consent form from each participating patient. The patients
were informed of their right to withdraw from the study at
any time. The randomisation was stratified by the centre
and by the severity of ischaemia. Randomisation was made
using closed envelopes. If the patient had bilateral SFA
occlusions, the leg first treated was randomised for this
study.
The protocol was sent to the sub-committee on Medical
Research Ethics of the National Advisory Board on Health
Care Ethics (ETENE), which forwarded it to the Ethics
Committee, Department of Surgery of the Hospital District
of Helsinki and Uusimaa. National statement was given and
the protocol was accepted on 9 December 2002 (Dnro HUS
529/E6/02, ETENE 142/04/02). The study was conducted in
accordance with the current version of the Declaration of




A total of 120 patients were to be randomised by January
2006 in 15 Scandinavian centres. Seven of them recruited
no patients, and even among the active centres the
recruitment rate turned out to be much slower than
expected. Therefore, the recruitment was extended by one
more year. Yet, only 44 patients had been randomised by
January 2007 despite a recruitment period of 41 months
and participation of eight centres (the number of patients
in Jyva¨skyla¨, 10; Helsinki, nine; Kuopio, nine; Oulu, seven;
Stockholm, three; Kolding, three; Lahti, two and Helsing-
borg, one).
Procedural success
Two endovascular interventions failed: one because re-
canalisation took place subintimally with the re-entry site
at low popliteal level, thus necessitating stenting instead of
thrupass, and the other because thrupass was not techni-
cally possible. There were more complications related to
thrupass than bypass (Table 3). In two instances, the
endovascular procedure was complicated by distal embo-
lisation, both of them necessitating thrombo-aspiration
during the procedure. There was no procedural mortality.Hospital stay was far shorter in patients treated with
thrupass than with bypass (Table 3). One leg was lost (at the
time of 17 months follow-up) in the bypass but there were
no amputations in the thrupass group. There also was one
death in the thrupass group (suicidal death after 2 months
follow-up) and two deaths in the bypass group (at 9 and 18
months).
Patency
A decision was made to terminate the trial due to the
results of the interim analysis and when recruiting had
continued for 42 months, and 28 patients had their 1-year
data available: 1-year primary patency (excluding technical
failures) was 48% for thrupass and 95% for bypass
(pZ 0.02). In addition, assisted primary patency as well as
secondary patency were significantly better after bypass
than thrupass procedure, irrespective of the inclusion or
exclusion of technical failures (all p< 0.05).
When the follow-up was extended, the life-table esti-
mates became grossly equilinear. The early failures held
the curves for thrupass markedly lower (Figs. 1 and 2) than
those for bypass with a 1-year primary patency (excluding
technical failures) of 46% for thrupass and of 84% for bypass
(pZ 0.18).
Figure 1 Primary patency excluding technical failures.
Figure 2 Secondary patency excluding technical failures.
582 M. Lepa¨ntalo et al.Primary, assisted primary and secondary patencies were
46%, 56% and 63% (technical failures excluded) or 42%, 51%
and 58% (technical failures included) for the thrupass group
and 84%, 89% and 100% for the bypass group, at 1 year,
respectively. The corresponding differences between
primary, assisted primary and secondary patencies were at
pZ 0.18, pZ 0.28 and pZ 0.05 level when technical fail-
ures were excluded, and pZ 0.09, pZ 0.14 and pZ 0.02
when technical failures were included.
Assessment of generalisability
Simultaneously with the onset of the recruitment in
Helsinki, collection of a sample of 100 consecutive digital
subtraction angiographies (DSAs) showing SFA occlusions
was started. It revealed only four occlusions that fulfilled
the inclusion criteria. The main angiographic reason for
excluding the patient was that the segments adjacent to
the occlusion were too diseased to offer a safe landing zone
for the endograft or bypass.
Discussion
A real problem of treating lower limb ischaemia and trying
to compare different modes of treatment is that it is very
difficult to standardise the disease treated.9 A good
example of this is the puzzling classification of femo-
ropopliteal lesions by TASC documents which mix together
different types of stenoses, occlusions and lesion charac-
teristics and change over time.10,11 The large BASIL trial
attempted to overcome this problem by using the uncer-
tainty approach e patients were included if both the
surgeon and angioradiologist were uncertain about the best
treatment to be used.12 Yet, the BASIL trial represented
a limited study sample and had a number of confounding
factors, such as: (1) angiographic inclusion criteria were not
used, (2) both femoropopliteal and infrapopliteal lesions
were included, (3) inclusion criteria were not reproducible
and (4) as only 11% of eligible patients were included, the
study had low external validity. This, of course, was the
case also with the present study as only 4% of femoralocclusions were suitable for this study. The results obtained
in the present study are not generalisable for all SFA
disease but only to a clearly definable subgroup with
moderate to long superficial artery occlusion. The treated
segments corresponded mostly to the Imelda Ia classifica-
tion, that is, occlusion ranging from 5 to 20 cm.13 A
prerequisite for inclusion was the necessity for healthy
inflow and outflow segments adjacent to the occlusion to
enable reliable fixation of the endograft. This attempt to
accept only femoral occlusions most suitable for endovas-
cular intervention was likely to bias the results in favour of
the thrupass rather than the bypass. Thus, the apparent
inferiority of the thrupass is likely to be even truer in
circumstances less favourable for endografting.
Previous case series have reported primary 1-year
patencies ranging from 58% to 93%,5,7,14e19 but the lesions
treated were not well defined. The first randomised trial
comparing bypass and thrupass was recently published by
Kedora et al.20 They included both stenoses and occlusions
and published almost equal patencies of around 75% at 1
year for thrupass and bypass. The thrupass results of their
study resembled those reported in a case series by Lammer,
which did not differentiate between the treatment of
stenotic and occluded segments.6 So far, endovascular
interventions have tended to worse results in the treatment
of occlusions than of stenoses, whereas bypassing a stenosis
always leaves a competing channel to threaten the patency
of the graft. Our thrupass results resemble those by Verta
et al.21 The PTFE bypass patency of the present study is in
accordance with other randomised studies.22 Overall, the
use of PTFE for claudication may be seen as dubious as
recent data have been published stating that the preser-
vation of the great saphenous vein for later use is
inexpedient.23
Although the present study began in August 2003 as the
first randomised controlled trial comparing bypass and
thrupass, this position was lost as the rate-limiting step of
recruitment appeared to be the recognition of an adequate
number of patients with TASC IIB or C (or Imelda Ia or II)
occlusions with healthy adjacent segments. The use of
well-defined inclusion criteria makes it easier to interpret
Bypass or Thrupass for SFA Occlusion? 583the results but slows down recruitment, decreases the
study sample and may compromise the external validity.
Thus a problem typical of this and many other studies is
that the outcome results are quickly outdated. At the same
time, questions can be raised whether the endograft
technique was mature and the angioradiologists trained
well enough. Indeed, the prerequisite for the angioradiol-
ogists was to have a wide endovascular experience but only
a minimum of three successful femoral endograftings. A
distinct finding was that the failures after thrupass
occurred in the early post-procedural phase. Another con-
founding factor was the non-standardised antithrombotic
drug regimen after the interventions, although efforts to
minimise bias were made by attempts to standardise it
within centres irrespective of treatment.
Since there are always new devices in the pipeline, the
problem is that the target is continuously changing. As
a solution, Lilford et al. suggested the tracker study
model,24 which tracks progress over time, has a flexible
protocol, no fixed number of patients and allows new
technologies to be included along the way.
Randomised controlled trials are aimed for issues of
uncertainty and give a momentary picture and are often
obsolete when published. Yet, at this point, it seems that
thrupass cannot overcome bypass under the circumstances
presented in the current study. As the outcome differed
markedly in favour of bypass, there was no justification for
comparison for secondary end-points, other than patency.
Appendix 1
Scandinavian Thrupass Study Group
Principal investigators:
Mauri Lepa¨ntalo, Department of Vascular Surgery, Hel-
sinki University Central Hospital, Finland.
David Bergqvist, Department of Vascular Surgery,
Academic Hospital, Uppsala University, Sweden.
Participating centres
Finland:
Helsinki, Helsinki University Central Hospital
Mauri Lepa¨ntalo, Katariina Laurila, Wolf-Dieter
Roth, Kimmo Lappalainen
Jyva¨skyla¨, Central Finland Central Hospital
Perttu Rossi, Juha Lavonen
Kuopio, Kuopio University Hospital
Kimmo Ma¨kinen, Hannu Manninen, Erkki Kaukanen
Lahti, Pa¨ija¨t-Ha¨me Central Hospital
Jarkko Lehtonen, Antti Korpela, Jarmo Lottonen
Oulu, Oulu University Hospital




Peter Qvarfordt, Hans Lindgren
Stockholm, So¨dersjukhuset
Peter Konrad, Martin Delle
Denmark:
Kolding, Fredericia og Kolding Sygehuse
Mariusz Zakrzewski, Johnny ChristensenData collection and monitoring
Anita Ma¨kela¨, Helsinki University Central Hospital
Data analysis
Anita Ma¨kela¨, Pekka Aho, Helsinki University Central
Hospital
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